SCHEMBL2990937

SCHEMBL2990937

O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C1CCNCC1

nearest known ligand 0.92

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 2/20 0.92
ADRA1A P35348 15/20 0.74
HRH1 P35367 15/20 0.74
ADRA1B P35368 15/20 0.74
HRH3 Q9Y5N1 10/20 0.74
KCNH2 Q12809 3/20 0.69
ADRA2A P08913 2/20 0.69
CHRM1 P11229 2/20 0.69
ADRA2B P18089 2/20 0.69
HTR2A P28223 2/20 0.69
DRD3 P35462 2/20 0.69
CHRM2 P08172 1/20 0.69
ADRB1 P08588 1/20 0.69
CYP2D6 P10635 1/20 0.69
GABRA1 P14867 1/20 0.69
ADRA2C P18825 1/20 0.69
SLC6A2 P23975 1/20 0.69
HTR2C P28335 1/20 0.69
SLC6A4 P31645 1/20 0.69
OPRM1 P35372 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Desmethylazelastine SCHEMBL2820100 0.96 ABCB1 (1.00) ABCB1ADRA1AHRH1ADRA1BHRH3
Desmethylazelastine SCHEMBL31427639 0.96 ABCB1 (1.00) ABCB1ADRA1AHRH1ADRA1BHRH3
Desmethylazelastine SCHEMBL10561389 0.95 ABCB1 (0.98) ABCB1ADRA1AHRH1ADRA1BHRH3
SCHEMBL10762965 0.88 ABCB1 (0.73) ABCB1ADRA1AHRH1ADRA1BHRH3
SCHEMBL10764377 0.84 ABCB1 (0.81) ABCB1ADRA1AHRH1ADRA1BHRH3
SCHEMBL10555870 0.84 ABCB1 (0.81) ABCB1ADRA1AHRH1ADRA1BHRH3
SCHEMBL10552975 0.84 ABCB1 (0.80) ABCB1ADRA1AHRH1ADRA1BHRH3
SCHEMBL2738787 0.84 ABCB1 (0.80) ABCB1ADRA1AHRH1ADRA1BHRH3
Azelastine SCHEMBL17803891 0.81 ADRA1A (1.00) ABCB1ADRA1AHRH1ADRA1BHRH3
Azelastine SCHEMBL4240 0.81 ADRA1A (1.00) ABCB1ADRA1AHRH1ADRA1BHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100184770-A1 COMPOUNDS GLAXO GROUP LIMITED 2010-07-22 US disclosed
US-20100184770-A1 COMPOUNDS GLAXO GROUP LIMITED 2010-07-22 US disclosed
US-20100184770-A1 COMPOUNDS GLAXO GROUP LIMITED 2010-07-22 US disclosed
EP-2091538-B1 4-BENZYL-1(2H)-PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS GLAXO GROUP LTD (GB) 2010-03-03 EP disclosed
EP-2091538-B1 4-BENZYL-1(2H)-PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS GLAXO GROUP LTD (GB) 2010-03-03 EP disclosed
EP-2091538-A2 4-BENZYL-L(2H)-PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS Glaxo Group Limited (GB) 2009-08-26 EP disclosed
WO-2008074803-A2 4-BENZYL-L ( 2H) -PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2008-06-26 WO disclosed
WO-2008074803-A2 4-BENZYL-L ( 2H) -PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184770-A1 COMPOUNDS CMA1, TSLP, IL5 ABCB1 285/4885ADRA1A 592/4885HRH1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.